

PARKINSON'S DISEASE (PD)**Saturday, March 28, 2020****07:30-08:30 E-Poster Presentations (Exhibition Area)****08:30-10:10 DEEP BRAIN STIMULATION (DBS)**Chairs: **Xiao-Ping Wang**, China |**08:30-09:20 When is the right time to refer PD patients for deep brain stimulation (DBS)?**

Capsule: DBS is effective in treating medication-refractory symptoms (motor and non-motor) and improves patients' quality of life in advanced PD. Currently, it is usually performed in late stage of PD. Advances in our understanding of the natural history of the disease, improved surgical techniques, brain imaging and device design require us to re-evaluate whether the right time for DBS is in earlier stages of the disease.

08:30-08:40 Host: **Mike Samuel**, UK08:40-08:55 Late: **Patricia Limousin**, UK08:55-09:10 Early: **Vladimira Vuletic**, Croatia

09:10-09:20 Discussion and rebuttals

09:20-10:10 DBS effectiveness against nonmotor features in PD is similar to those of infusion therapies.

Capsule: DBS and infusion therapies are both recognized as therapeutic approaches in the treatment of motor symptoms in advanced stage PD when patients develop "wearing off" and/or dyskinesias with oral dopaminergic medication. However, the effects of these two therapeutic approaches on nonmotor features are still under debate.

09:20-09:30 Host: **Fiona Gupta**, USA09:30-09:45 Yes: **Abdelhamid Benazzouz**, France09:45-10:00 No: **Keyoumars Ashkan**, UK

10:00-10:10 Discussion and rebuttals

10:10-10:25 Coffee Break**10:25-12:05 CONTROVERSIES IN CLINICAL APPROACH**Chairs: **Milica Kramberger**, Slovenia | **Diego Santos Garcia**, Spain**10:25-11:15 Clinical assessment in PD - Motor assessment is the key and nonmotor is marginal.**

Capsule: PD is primarily a motor disorder, yet non-motor symptoms (NMS) become more widely recognized. How important are these NMS in the clinical assessment of the patient?

10:25-10:35 Host: **Gennaro Pagano**, UK

10:35-10:50 Yes:

10:50-11:05 No: **Pedro Garcia Ruiz**, Spain

11:05-11:15 Discussion and rebuttals

11:15-12:05 Should untroubling dyskinesias be treated?

Capsule: Dyskinesia occurs frequently in advanced PD patients treated with dopaminergic medications. The dyskinesia frequently is troubling to spouses or caregivers more than to the patients themselves, particularly in mild cases. Should these patients still be treated?

11:15-11:25 Host: **Daniel Kremens**, USA11:25-11:40 Yes: **Rajesh Pahwa**, USA11:40-11:55 No: **Ray Chaudhuri**, UK

11:55-12:05 Discussion and rebuttals

12:05-12:15 Short Break**12:15-13:15 Industry Supported Symposium |****13:15-14:15 Lunch Break****13:15-14:15 Meet the Expert |****14:15-15:45 GENES AND ENVIRONMENT**

Chairs:

14:15-15:00 Should PD patients carrying GBA mutations be treated differently from gene mutation negatives?

14:15-14:25	Host: Vladimira Vuletic , Croatia
14:25-14:40	Yes: Anthony Schapira , UK
14:40-14:55	No: Rajesh Pahwa , USA
14:55-15:00	Discussion and rebuttals
15:00-15:45	Are there important environmental factors for PD? <i>Capsule: The pathogenesis of the neurodegenerative processes in PD are not well understood. Although several genes were found to be associated with the development of PD, the causative agents for a great percent of cases remain unclear. Various factors were incriminated to increase the risk of PD development yet their interactions with genetic factors are unknown.</i>
15:00-15:10	Host: Alastair Noyce , UK
15:10-15:25	Yes: Cristian Falup-Pecurariu , Romania
15:25-15:40	No: Zvezdan Pirtosek , Slovenia
15:40-15:45	Discussion and rebuttals
15:45-16:00	Coffee Break
16:00-19:00	CONTROVERSIES IN PD ETIOPATHOGENESIS
Chairs:	
16:00-16:50	Is CSF alpha-synuclein a useful biomarker for PD? <i>Capsule: A change in the content of α-synuclein (α-syn) in CSF is considered as a promising biomarker of PD. Indeed, the total α-syn content in CSF decreases, and the fractions of phosphorylated and oligomeric α-syn increase in PD. However, all attempts to use α-syn as a biomarker for differential diagnosis or prognosis were unsuccessful. Can CSF α-syn be used as a biomarker?</i>
16:00-16:10	Host: Michael Ugrumov , Russia
16:10-16:25	Yes: Georgia Xiromerisiou , Greece
16:25-16:40	No: Mark F. Lew , USA
16:40-16:50	Discussion and rebuttals
16:50-17:40	Is continuous dopaminergic stimulation better strategy than pulsatile in every patient? <i>Capsule: Dopaminergic stimulation is the key treatment for PD. However, it is still debatable whether pulsatile stimulation is responsible for the development of dyskinesias.</i>
16:50-17:00	Host: Fernando Pagan , USA
17:00-17:15	Yes: Stuart Isaacson , USA
17:15-17:30	No:
17:30-17:40	Discussion and rebuttals
17:40-18:10	The personalized Parkinson's Ray Chaudhuri , UK
18:10-18:15	Discussion
18:15-19:00	CLINICAL PATHOLOGICAL CONFERENCE (CPC)
Chair:	Edwin Jabbari , UK
18:15-19:00	Case Presentation - A young man with parkinsonism Host: Tom Warner , UK Clinical: Helen Ling , UK Pathology: Tomas Revesz , UK Discussion